Please assess the completion status of the following clinical trial:

Trial Title: ECGi Ibutilide: Effect of Ibutilide on AF Source Location and Organization

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 years of age.~* ° Symptomatic persistent AF refractory or intolerant to at least 1 class I or III antiarrhythmic medication Persistent AF - defined as Persistent: AF that is sustained \> 7 days. Episodes of AF which are terminated by electrical or pharmacologic cardioversion after ≥ 48 hours of AF, but prior to 7 days, should also be classified as persistent AF episodes.~  * Planned to undergo first catheter ablation procedure ( prior atrial flutter typical is allowed)~* Ability to understand the requirements of the study and sign the informed consent form.~* Willingness to adhere to study restrictions and comply with all post-procedural follow-up requirements~* Projected lifespan greater than 1 year~Exclusion Criteria:~* They have baseline prolonged QT or renal failure precluding safe used of ibutilide~* Rheumatic heart disease,~* Current intra-cardiac thrombus,~* History of MI or CABG within 6 weeks;~* Class IV HF,~* Unable to sign consent~* Projected lifespan of \< 1 year~* Women known to be pregnant or to have positive beta-HCG.~* Participation in another study that would interfere with this study.~* Unstable Angina~* Recent cerebral ischemic events~* Contraindication to anticoagulation~* Prior history of polymorphic ventricular tachycardia or torsades de pointes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with AF (Type: EXPERIMENTAL): Patients with AF and planned to undergo first catheter procedure

Based on this trial design, predict the completion outcome and termination type (if applicable).